3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Urinary Bladder Neoplasms
8
Carcinoma, Merkel Cell
6
Neoplasm Metastasis
5
Carcinoma, Transitional Cell
5
Breast Neoplasms
5
Carcinoma, Renal Cell
4
Triple Negative Breast Neoplasms
2
Skin Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neuroendocrine Tumors
2
Melanoma
2
Carcinoma, Non-Small-Cell Lung
2
Uveal Melanoma
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Thymoma
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Primary Myelofibrosis
1
Penile Squamous Cell Carcinoma (PSCC)
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasms
1
Neoplasm, Residual
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Metastatic Urothelial Cancer
1
Mesothelioma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Interventions
Cisplatin
11
pembrolizumab
10
Carboplatin
7
Radiotherapy
6
Cetuximab
6
Docetaxel
5
Surveys and Questionnaires
3
Radiotherapy, Intensity-Modulated
3
Paclitaxel
3
Cyclophosphamide
3
fludarabine
2
cemiplimab
2
atezolizumab
2
aldesleukin
2
Surgical Procedures, Operative
2
Standard of Care
2
Radiation
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Fluorouracil
2
Drug Therapy
2
vistusertib
1
toripalimab
1
sitravatinib
1
palbociclib
1
osimertinib
1
olaparib
1
niraparib
1
lenvatinib
1
fludarabine phosphate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Squamous Cell
×
avelumab
×
90 days
×
Clear all
NCT03494322
2026-05-20
EACH
University College, London
Phase 2
Completed
16 enrolled